Labat AfricaJSE:LAB EV-to-OCF is 8.70 as of Jul. 11, 2026, which is 106% above its 10-year median of 4.22. The stock has 5 warning signs investors should review. Among 1,008 Drug Manufacturers companies, Labat Africa ranks better than 55.16% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Labat Africa's Enterprise Value is R237.3 Mil.
Labat Africa's Cash Flow from Operations for the trailing twelve months (TTM) ended in Nov. 2025 was R27.3 Mil. Therefore, Labat Africa's EV-to-OCF for today is 8.70.
The historical rank and industry rank for Labat Africa's EV-to-OCF or its related term are showing as below:
JSE:LAB'
s EV-to-OCF Range Over the Past 10 Years
Min: -88.44 Med: 4.22 Max: 61.51
Current: 8.7
During the past 13 years, the highest EV-to-OCF of Labat Africa was 61.51. The lowest was -88.44. And the median was 4.22.
JSE:LAB's EV-to-OCF is ranked better than 55.16% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 10.575
vs JSE:LAB: 8.70
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Labat Africa's PE Ratio (TTM) for today is calculated as:
Labat Africa's share price for today is R0.03.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Labat Africa's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Nov. 2025 was R0.134.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Labat Africa EV-to-OCF Related Terms
Labat Africa EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Labat Africa's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Labat Africa's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Labat Africa EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Labat Africa's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Labat Africa's EV-to-OCF falls into.
Labat Africa's current Enterprise Value is R237.3 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Labat Africa's Cash Flow from Operations for the trailing twelve months (TTM) ended in Nov. 2025 was R27.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Labat Africa (JSE:LAB) has a EV-to-OCF of 8.70 as of Jul. 11, 2026. This is 106% above median its historical median of 4.22. According to the industry distribution chart, Labat Africa ranks #452 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 44.8%.
Is Labat Africa's EV-to-OCF too high?
Labat Africa's current EV-to-OCF of 8.70 is 106% above median its 10-year median of 4.22. The Drug Manufacturers industry median EV-to-OCF is 10.58. Labat Africa's value of 8.70 is 17.7% below this industry median. Based on the distribution chart, Labat Africa ranks #452 out of 1008 companies in the Drug Manufacturers industry, which is above the industry midpoint.
How does Labat Africa's EV-to-OCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Labat Africa ranks #452 out of 1008 companies for EV-to-OCF. This puts Labat Africa in the upper half of its industry. The industry median EV-to-OCF is 10.58. Labat Africa's value of 8.70 is 17.7% below this benchmark. While the company's 10-year median is 4.22 vs. the industry median of 10.58, Labat Africa has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 10.58, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Labat Africa's current EV-to-OCF of 8.70 is 17.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 10.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Labat Africa's current EV-to-OCF is 8.70, which is 106% above median its own 10-year median of 4.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labat Africa stock overvalued right now?
Based on GuruFocus' analysis, Labat Africa (JSE:LAB) is currently considered Possible Value Trap. The stock's GF Value™ is R0.18, compared to a current price of R0.03 — trading 83.3% below its estimated fair value. The current EV-to-OCF is 8.70, which is 106% above median its 10-year median of 4.22 and 17.7% below the Drug Manufacturers industry median of 10.58. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Labat Africa (JSE:LAB), the current EV-to-OCF is 8.70 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Labat Africa Ltd is an investment holding company. Through its subsidiaries, the company operates in the following segments; Technology, Head office, and Healthcare. The Technology segment manufactures and distributes integrated circuits South African Micro - Electronic Systems. Head office operations provide management services, logistics and seeks further investment opportunities for the Group. The Healthcare segment generates maximum revenue for the company and focusses on medical cannabis industry in South Africa. Geographically, the company carries out its business operations in South Africa.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JSE:LAB has been successfully added to your 